HQL

Abrdn Life Sciences Investors
CAPPED RATING

Abrdn Life Sciences Investors (HQL) is rated C- (1.9/5) on Deltasharpe Prism, scored against Financial Services sector peers. Its strongest pillar is Profitability (C+); its weakest is Growth (F). The rating has held at C- for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
C-
Factor Score 2.0 / 5.0
Growth
F
Factor Score 0.1 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C+
Factor Score 2.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 2.8
EV / EBITDA N/A
Rev Growth YoY -60.8%
Gross Margin N/M
Price Return 3M -7.8%
Price Return 12M 33.3%
Catalyst Signal 0.00
Market Cap $576.2M
TTM Revenue $1.1M
Price / Sales 519.2
ROE 41.4%

Historical Factor Score Progression

Held C- for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C- (2.0) F (0.1) C+ (2.6) C (2.4) C+ (2.5) C- (1.9)
2026-11-05 C- (2.0) F (0.1) C+ (2.6) C (2.5) C+ (2.6) C- (2.0)
2026-10-29 C- (2.0) F (0.1) C+ (2.6) B (3.2) C+ (2.5) C- (2.1)
2026-10-22 C- (2.0) F (0.2) C+ (2.6) B (3.3) C+ (2.5) C- (2.1)
2026-10-15 C- (2.0) F (0.2) C+ (2.6) B- (3.0) C+ (2.5) C- (2.1)
Page 1 of 4